The global anti-nuclear antibody testing market is at the forefront of modern immunology, providing the primary screening tool for identifying systemic autoimmune disorders. ANA tests detect autoantibodies that target the nucleus of a patient’s own healthy cells, serving as a critical indicator for conditions such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis, and...
The U.S. allergy and autoimmune disease diagnostics market, valued at USD 4.24 billion in 2024, is anticipated to expand at a CAGR of 8.5% from 2025 to 2034, with growth increasingly driven by segment-wise performance across product types, end-user applications, and technological platforms. The market can be segmented by product type into immunoassay analyzers, reagent kits, rapid tests, and...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek